ArticleFrontiers in psychiatry2025
Sex-informed estrogen receptor modulation in schizophrenia: a male-focused ERβ/GPER1 framework for cognitive and negative symptoms.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment-resistant schizophrenia (TRS) remains a major unmet clinical need, particularly in males who exhibit more severe negative and cognitive symptoms and limited responsiveness to dopamine-based therapies. Estrogenic signaling-especially through estrogen receptor beta (ERβ) and the G-protein-coupled estrogen receptor 1 (GPER1)-has emerged as a promising neuromodulatory target for these domains. This review synthesizes evidence supporting selective estrogen receptor modulators (SERMs), with an emphasis on raloxifene, as adjunctive agents capable of engaging central estrogenic pathways without feminizing systemic effects. Preclinical, stem cell-derived, and clinical data demonstrate that ERβ- and GPER1-mediated signaling enhances synaptic plasticity, mitochondrial stability, anti-inflammatory glial states, and dopaminergic-glutamatergic balance-core processes implicated in TRS pathophysiology. Complementary findings involving aromatase activity, neurosteroidogenesis, and genetic variation in ESR2 and CYP19A1 highlight opportunities for biomarker-guided stratification. The review also addresses ethical and gender-inclusive considerations, framing estrogenic modulation as sex-informed but not sex-restricted, given the universal expression of ERβ and GPER1 across sexes. Finally, emerging innovations-including GPER1-biased ligands, tissue-selective estrogen complexes, and nanoparticle delivery systems-are discussed as strategies to optimize central nervous system targeting while minimizing peripheral risk. Together, these insights position receptor-selective estrogenic modulation as a mechanistically grounded and clinically relevant approach for improving cognitive and negative symptom outcomes in TRS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.